MannKind Completes Patient Randomization in Phase 1b Idiopathic Pulmonary Fibrosis Study

MT Newswires Live

06/03

MannKind (MNKD) said Wednesday that it has completed patient randomization in its US Phase 1b INFLO-1 clinical trial evaluating nintedanib DPI for idiopathic pulmonary fibrosis, a chronic lung disease.

MannKind said it expects to report data from the INFLO-1 study in Q3, providing an initial clinical assessment of safety, tolerability, and pharmacokinetics in patients with idiopathic pulmonary fibrosis.

Additionally, the company said it has enrolled the first of an expected 210 participants in its global Phase 2 INFLO-2 study, set to be conducted across about 85 sites.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2640590616"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2640590616\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2640590616?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 19:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640590616","market":"hk","top_or_hot":-1,"title":"MannKind Completes Patient Randomization in Phase 1b Idiopathic Pulmonary Fibrosis Study","media":"MT Newswires Live","content":"<html><body><p> MannKind (MNKD) said Wednesday that it has completed patient randomization in its US Phase 1b INFLO-1 clinical trial evaluating nintedanib DPI for idiopathic pulmonary fibrosis, a chronic lung disease.</p><p>MannKind said it expects to report data from the INFLO-1 study in Q3, providing an initial clinical assessment of safety, tolerability, and pharmacokinetics in patients with idiopathic pulmonary fibrosis.</p><p>Additionally, the company said it has enrolled the first of an expected 210 participants in its global Phase 2 INFLO-2 study, set to be conducted across about 85 sites.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MannKind Completes Patient Randomization in Phase 1b Idiopathic Pulmonary Fibrosis Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMannKind Completes Patient Randomization in Phase 1b Idiopathic Pulmonary Fibrosis Study\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-06-03 19:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> MannKind (MNKD) said Wednesday that it has completed patient randomization in its US Phase 1b INFLO-1 clinical trial evaluating nintedanib DPI for idiopathic pulmonary fibrosis, a chronic lung disease.</p><p>MannKind said it expects to report data from the INFLO-1 study in Q3, providing an initial clinical assessment of safety, tolerability, and pharmacokinetics in patients with idiopathic pulmonary fibrosis.</p><p>Additionally, the company said it has enrolled the first of an expected 210 participants in its global Phase 2 INFLO-2 study, set to be conducted across about 85 sites.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2640590616","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640590616","pubTimestamp":1780484648,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"MannKind (MNKD) said Wednesday that it has completed patient randomization in its US Phase 1b INFLO-1 clinical trial evaluating nintedanib DPI for idiopathic pulmonary fibrosis, a chronic lung disease","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4584":"避孕概念","MNKD":"曼恩凯德生物医疗"},"translate_title":"MannKind在1b期特发性肺纤维化研究中完成患者随机化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":1.5},"content_text":"MannKind (MNKD) said Wednesday that it has completed patient randomization in its US Phase 1b INFLO-1 clinical trial evaluating nintedanib DPI for idiopathic pulmonary fibrosis, a chronic lung disease.MannKind said it expects to report data from the INFLO-1 study in Q3, providing an initial clinical assessment of safety, tolerability, and pharmacokinetics in patients with idiopathic pulmonary fibrosis.Additionally, the company said it has enrolled the first of an expected 210 participants in its global Phase 2 INFLO-2 study, set to be conducted across about 85 sites.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}